Context

Since its foundation in 2010, Ginolis Ltd, headquartered in Oulu (Finland) and with subsidiaries across Europe and the US, has developed into a leading diagnostics automation provider focusing on automation workflows for medical devices and diagnostics.

The systems developed by Ginolis are used globally for the production of consumables for medical devices (such as cartridges for insulin pumps) and in-vitro diagnostics tests, including lateral flow tests and point-of-care (PoC) microfluidic tests.

In 2020, Ginolis’ controlling shareholder Verso Capital commissioned Bryan, Garnier & Co to find a suitable partner to support the accelerated growth and future expansion of the company.

The choice of Cellink AB created an opportunity to build a global leading bio-convergence business and to bring Ginolis’ expertise, products and workflow automation solutions to Cellink’s substantial customer base.

This acquisition enables Cellink to cater for processes from early R&D to standardized large-scale high-throughput production. Ginolis’ strong offer in diagnostic automation solutions for the medical device and diagnostic industries can be fully integrated with Cellink’s current offering and its customers’ workflows. The transaction is expected to generate substantial synergies around innovation and joint future product development. Ginolis will be integrated into Cellink’s industrial automation segment together with Scienion, one of Ginolis’ long-term partners.

Ginolis_website_tombstone

About Ginolis

Ginolis is an Oulu (Finland) headquartered technology-driven diagnostics automation company focusing on automation workflows for medical device and diagnostics leaders. The Company was founded in 2010 and employs around 100 people in its assembly sites and sales offices in Finland, Estonia, Sweden, the UK, China, and the US. Ginolis is a leading player in the diagnostics automation segment and offers a range of modular systems for precise manufacturing of multiplex and lateral-flow Point-of-Care tests.

Ginolis has experienced tremendous growth over the past years, with a compound growth rate higher than 120% since 2018 to reach EUR 18m in 2020.

Discover Ginolis

About Cellink

Founded in 2016, Cellink is a global publicly listed leader in bio-convergence that focusses on the application areas of bioprinting, multiomics, cell line development, and diagnostics. The company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. Cellink’s products are trusted by more than 1,800 laboratories and are being used in more than 65 countries.

Discover Cellink

Falk Müller-Veerse

Investment Banking

Falk Müller-Veerse photo

Luc Springinsfeld

Investment Banking

Luc Springinsfeld photo

Martin Eichler

Investment Banking

Martin Eichler photo

Felix Straeussl

Investment Banking

Felix Straeussl photo

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center